That is a great analysis fletch...thanks for posting. I was a Sarepta shareholder through the accelerated approval process for eteplirsen a few years back. I think that process may have helped pave the way for these rare disease drugs somewhat. From the PR today and falconer's analysis, it appears that A-273 is in a better position on the three fronts he points out for accelerated approval than the DMD indication Sarepta had back then and it was ultimately approved. This is all IMHO of course.